Global Migraine Treatment Medication Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Migraine Treatment Medication Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Migraine is a neurological condition that typically causes painful headache attacks that occur with additional symptoms, such as sensitivity to light, sound, smell, or touch. Migraine treatment medications aim to alleviate or prevent migraine headaches.
Migraine Treatment Medication report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Migraine Treatment Medication market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Acute Migraine and Chronic Migraine are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Migraine Treatment Medication industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Migraine Treatment Medication key companies include GSK, Pfizer, Novartis, Teva, Sun Pharma, Grünenthal, Endo Pharmaceuticals, Merck and Johnson & Johnson, etc. GSK, Pfizer, Novartis are top 3 players and held % share in total in 2022.
Migraine Treatment Medication can be divided into Triptans, NSAIDs and Others,, etc. Triptans is the mainstream product in the market, accounting for % share globally in 2022.
Migraine Treatment Medication is widely used in various fields, such as Acute Migraine and Chronic Migraine, etc. Acute Migraine provides greatest supports to the Migraine Treatment Medication industry development. In 2022, global % share of Migraine Treatment Medication went into Acute Migraine filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Migraine Treatment Medication market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
GSK
Pfizer
Novartis
Teva
Sun Pharma
Grünenthal
Endo Pharmaceuticals
Merck
Johnson & Johnson
AbbVie
Abbott
Bayer
Eli Lilly
Kowa Pharmaceuticals America
AstraZeneca
Segment by Type
Triptans
NSAIDs
Others
Acute Migraine
Chronic Migraine
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Migraine Treatment Medication market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Migraine Treatment Medication introduction, etc. Migraine Treatment Medication Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Migraine Treatment Medication market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Migraine Treatment Medication report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Migraine Treatment Medication market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Acute Migraine and Chronic Migraine are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Migraine Treatment Medication industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Migraine Treatment Medication key companies include GSK, Pfizer, Novartis, Teva, Sun Pharma, Grünenthal, Endo Pharmaceuticals, Merck and Johnson & Johnson, etc. GSK, Pfizer, Novartis are top 3 players and held % share in total in 2022.
Migraine Treatment Medication can be divided into Triptans, NSAIDs and Others,, etc. Triptans is the mainstream product in the market, accounting for % share globally in 2022.
Migraine Treatment Medication is widely used in various fields, such as Acute Migraine and Chronic Migraine, etc. Acute Migraine provides greatest supports to the Migraine Treatment Medication industry development. In 2022, global % share of Migraine Treatment Medication went into Acute Migraine filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Migraine Treatment Medication market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
GSK
Pfizer
Novartis
Teva
Sun Pharma
Grünenthal
Endo Pharmaceuticals
Merck
Johnson & Johnson
AbbVie
Abbott
Bayer
Eli Lilly
Kowa Pharmaceuticals America
AstraZeneca
Segment by Type
Triptans
NSAIDs
Others
Segment by Application
Acute Migraine
Chronic Migraine
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Migraine Treatment Medication market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Migraine Treatment Medication introduction, etc. Migraine Treatment Medication Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Migraine Treatment Medication market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices